Follow
Christopher Giuliano
Title
Cited by
Cited by
Year
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
A Lin, CJ Giuliano, A Palladino, KM John, C Abramowicz, ML Yuan, ...
Science translational medicine 11 (509), 2019
5492019
Structure of the mitochondrial inner membrane AAA+ protease YME1 gives insight into substrate processing
C Puchades, AJ Rampello, M Shin, CJ Giuliano, RL Wiseman, SE Glynn, ...
Science 358 (6363), 2017
2042017
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials
A Lin, CJ Giuliano, NM Sayles, JM Sheltzer
Elife 6, e24179, 2017
1372017
Generating single cell–derived knockout clones in mammalian cells with CRISPR/Cas9
CJ Giuliano, A Lin, V Girish, JM Sheltzer
Current protocols in molecular biology 128 (1), 2019
1282019
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
CJ Giuliano, A Lin, JC Smith, AC Palladino, JM Sheltzer
Elife 7, e32838, 2018
862018
B-cell-specific checkpoint molecules that regulate anti-tumour immunity
L Bod, YC Kye, J Shi, E Torlai Triglia, A Schnell, J Fessler, SM Ostrowski, ...
Nature, 1-9, 2023
372023
FABP1 controls hepatic transport and biotransformation of Δ 9-THC
MW Elmes, LE Prentis, LL McGoldrick, CJ Giuliano, JM Sweeney, ...
Scientific reports 9 (1), 1-13, 2019
222019
A positive feedback loop controls Toxoplasma chronic differentiation
MH Licon, CJ Giuliano, AW Chan, S Chakladar, JN Eberhard, ...
Nature microbiology, 1-16, 2023
192023
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11
A Lin, CJ Giuliano, A Palladino
172019
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11: eaaw8412
A Lin, CJ Giuliano, A Palladino, KM John, C Abramowicz, ML Yuan, ...
162019
Functional profiling of the Toxoplasma genome during acute mouse infection
CJ Giuliano, KJ Wei, FM Harling, BS Waldman, MA Farringer, ...
bioRxiv, 2023.03. 05.531216, 2023
82023
Abstract B44: Lysyl oxidases suppress pancreatic cancer progression and inhibit FAK and ERK signaling
M Shields, P Maguin, C Giuliano, S Dallas, JE Wilkinson, M Egeblad
Cancer Research 78 (10 Supplement), B44-B44, 2018
2018
Identification and characterization of survival-associated genomic features across tumor types
J Smith, A Lin, C Giuliano, JM Sheltzer
Cancer Research 77 (13 Supplement), 390-390, 2017
2017
Abstract 2149A: CRISPR/Cas9 mutagenesis invalidates a genetic target of clinical trials in cancer
A Lin, C Giuliano, N Sayles, J Smith, J Sheltzer
Cancer Research 77 (13 Supplement), 2149A-2149A, 2017
2017
Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer
CJ Giuliano, A Lin, JC Smith, AC Palladino, JM Sheltzer
BioRxiv, 203984, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–15